Transactions

Catalyst Pharmaceuticals Inc.’s license of development and commercial rights to Vamorlone in North America and concurrent equity investment in Santhera

Date Announced:
06/20/2023

client:
Catalyst Pharmaceuticals Inc.

Status:
Closed – 07/19/2023

Value:
$231 million + royalties